ClinicalTrials.gg

Program

anbalcabtagene autoleucel

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Lupus Nephritis, led by Curocell.

Furthest: phase 2, since Apr 5, 20212 company-led studies, 2 open or runningNext primary completion: Jun 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Curocell22 open or runningphase 2since Apr 5, 2021Apr 5, 2021Jun 2030phase 2 · NCT07364396

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 5, 2021First study: phase 2 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT04836507 · 91 planned · South Korea
  2. Aug 20, 2025Phase 2 study in Lupus NephritisNCT07364396 · 39 planned

Ahead

  1. Jun 2030Primary completion: phase 2 study in Lupus NephritisNCT07364396
  2. Aug 15, 2030Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04836507

TargetBeta

CD19 →read by rule
“A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, ”NCIt, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07364396Lupus Nephritis2Not yet recruitingJun 203039
NCT04836507Lymphoma, Large B-Cell, Diffuse · South Korea2RecruitingAug 15, 203091

How it is read

Names in the registry

  • “CRC01”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.